Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract

ConditionCataract
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
AgeUp to 3
SponsorEyePoint Pharmaceuticals, Inc.

About this trial

A Phase 3/4, Prospective, Randomized, Active Treatment-Controlled, Parallel-Design, Multicenter Study to Evaluate the Safety of DEXYCUfor the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Undergoing uncomplicated cataract surgery with or without a posterior chamber intraocular lens (IOL) implantation.

If a contact lens is used for correction of post-operative aphakia, it must be a silicone elastomer lens or a rigid gas permeable lens (no water content).

Other protocol-specified inclusion criteria may apply.

Disqualifiers

Presence of clinically significant gastrointestinal, cardiovascular, hepatic, renal, hematological, endocrine, neurological, psychiatric, respiratory, or other medical condition that could increase the risk to the subject as determined by the investigator.

Has a post-traumatic cataract.

Presence of active or suspected viral, bacterial, or fungal disease in the study eye.

Ocular hypertension with an IOP in the study eye >25 mmHg at Screening with or without treatment with anti-glaucoma monotherapy.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Dexamethasone

    Drug

    single anterior chamber injection

  • Prednisolone Acetate Ophthalmic

    Drug

    topical administration four times a day for 28 days, followed by treatment taper

Treatment groups

60 Participants
are divided into 2 treatment groups
Group A: DEXYCU (dexamethasoneintraocular suspension) 9%Experimental treatment 1 intervention
Group B: Prednisolone acetate ophthalmic suspension (USP) 1%Active comparator 1 intervention

Trial outcomes

Primary outcomes

1

Grade of anterior chamber cells (ACC)

Time frame
Post-Operative Day 14

Secondary outcomes

1

Grade of anterior chamber flare (ACF)

Time frame
Post-Operative Day 14

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.